Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive ( A 1971 biology graduate with honors from Texas Tech University, he earned his MD from UT Southwestern Medical School, completed residency at Parkland Hospital, and fellowship in hematology-oncology at UCLA, where he served as Associate Professor of Medicine for nearly a decade ( In 1991, he returned to UT Southwestern as Professor of Medicine and Microbiology, Chief of Molecular Virology, Chief of Hematology-Oncology, and Director of Simmons Cancer Center (

Gaynor joined the pharmaceutical industry in 2002 as VP of Cancer Research at Eli Lilly, rising to SVP of Oncology Clinical Development before retiring in 2016 ( He then led R&D at Neon Therapeutics (2016-2020) and became President of BioNTech US following its acquisition ( He serves as a Director on Zai Lab Limited's Board (since 2019, Compensation Committee Chair), with an estimated net worth of at least $2 million as of May 2026 ( Previously or currently, he has directed Alkermes and Infinity Pharmaceuticals (

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.